Promising New Data Shows Otsuka’s Kidney Disease Drug Preserves Kidney Function, Offering Fresh Hope for IgA Nephropathy Patients

June 5, 2026 | Princeton, NJ — Otsuka Pharmaceutical announced Thursday that its FDA-approved drug VOYXACT (sibeprenlimab-szsi) successfully preserved kidney function over 12 months compared to a placebo in adults with primary immunoglobulin A nephropathy (IgAN). The findings, drawn from interim estimated glomerular filtration rate (eGFR) data from the ongoing Phase 3 VISIONARY trial, represent a critical milestone for the approximately 130,000 people in the United States living with this progressive autoimmune kidney disease. Because IgAN frequently leads to end-stage kidney disease (ESKD) requiring dialysis or an organ transplant, these newly released findings offer tangible hope for long-term disease modification.

Key Findings from the VISIONARY Trial

The interim analysis focuses on eGFR, which assesses the kidneys’ ability to filter waste and toxins from the blood. As the gold-standard metric for tracking the progression of kidney decline, the stabilizing eGFR data indicates that VOYXACT actively protects functional kidney tissue over a 12-month period.

This functional preservation builds directly upon earlier, remarkable data from the same trial evaluating proteinuria—the leakage of excess protein into the urine. Proteinuria serves as a recognized surrogate marker that strongly correlates with a delayed progression toward complete kidney failure.

12-Month Proteinuria Reduction Data

Beyond these percentages, the clinical outcomes are equally stark: approximately 34.3% of patients receiving VOYXACT achieved complete proteinuric remission at 12 months, compared to just 12.7% of those in the placebo cohort.

Understanding IgA Nephropathy

IgA nephropathy, historically known as Berger’s disease, is a condition where immunoglobulin A (an antibody meant to protect the body) accumulates incorrectly inside the kidneys. This accumulation triggers chronic inflammation that damages the delicate filtering units of the organ, causing blood and protein to leak into the urine.

The disease typically manifests in young adults aged 20 to 40. Under current standard care, a significant portion of these individuals experience an irreversible, lifelong decline that culminates in end-stage kidney disease.

How VOYXACT Works: Hitting the Source

VOYXACT represents a paradigm shift in treatment. It is a first-in-class monoclonal antibody designed to selectively inhibit a cytokine called APRIL (A Proliferation-Inducing Ligand), which drives the pathogenesis of IgAN.

To understand how VOYXACT works, it helps to visualize the disease as a four-step domino effect:

1. The Trigger: The cytokine APRIL promotes the survival of abnormal B cells, which produce a defective antibody called galactose-deficient IgA1 (Gd-IgA1).

2. The Blockade: Sibeprenlimab binds to and neutralizes APRIL, stopping this signal.

3. The Cleanup: Without the APRIL signal, the production of defective Gd-IgA1 decreases, preventing the formation of damaging immune complexes.

4. The Protection: Fewer immune complexes deposit in the kidneys, leading directly to reduced inflammation and a drastic drop in protein leakage.

“This is fundamentally different from corticosteroids, which cause broad B-cell suppression, and complement inhibitors,” explains Dr. Amit Kaushal, Assistant Professor of Medicine and Medical Director of Dialysis Units at West Virginia University School of Medicine, who is not involved in the trial. “Sibeprenlimab is the first IgAN therapy that targets the actual upstream driver of the disease.”

Expert Perspectives

The medical community has reacted with cautious optimism to the latest data. Dr. Dana Rizk, a professor of medicine in the division of nephrology at the University of Alabama at Birmingham, emphasized the strength of the clinical trial’s scale and outcomes.

“The VISIONARY Phase 3 interim analysis shows a robust proteinuria reduction of 51.2% in the group treated with sibeprenlimab relative to placebo,” said Dr. Rizk. “These results affirm our belief in the efficacy of sibeprenlimab in the largest Phase 3 IgAN trial to date.”

Dr. Rizk added that the emerging safety data is reassuring and provides clinicians with a highly anticipated therapeutic option that targets the root immunologic causes of the condition.

John Kraus, M.D., Ph.D., executive vice president and chief medical officer at Otsuka Pharmaceutical Development & Commercialization, echoed this sentiment. “Proteinuria control is an important independent predictor for long-term prognosis, and this interim data reinforces our belief that selectively targeting APRIL has the potential to be an effective and safe approach for this progressive and irreversible kidney disease.”

Safety Profile

The interim data revealed a favorable safety profile for VOYXACT, with adverse event rates tracking tightly alongside the placebo group:

• Treatment-emergent adverse events: 74.1% in the VOYXACT group vs. 82.1% in the placebo group.

• Serious adverse events: 3.9% for VOYXACT vs. 5.4% for placebo.

• Common mild infections: Upper respiratory tract infections (14.7% vs. 13.9%) and nasopharyngitis (12.4% vs. 10.0%) were the most frequent reports.

• Injection site reactions: Balanced at 24% for the active drug and 23% for the placebo.

• Critical safety markers: Crucially, there was no clinically meaningful signal for hypogammaglobulinemia (severe antibody depletion) at the quarterly 400 mg dose, no opportunistic infection signals, and zero deaths reported.

Trial Design and Regulatory Status

The U.S. Food and Drug Administration (FDA) granted accelerated approval to VOYXACT on November 25, 2025, aimed at reducing proteinuria in adults with primary IgAN who are at risk of rapid disease progression.

However, important regulatory context remains: the accelerated approval was granted based on proteinuria reduction as a surrogate endpoint. It has not yet been definitively established whether VOYXACT halts or slows long-term kidney function decline over several years. Continued FDA approval remains contingent upon the verification of definitive clinical benefits in the ongoing, confirmatory portion of the VISIONARY trial.

The VISIONARY study stands as the largest Phase 3 IgAN trial conducted to date, evaluating 510 to 530 adult patients with biopsy-confirmed primary IgAN across 240 sites in 31 countries. All participants received the current standard of care—including maximally tolerated background therapies like ACE inhibitors, ARBs, or SGLT2 inhibitors. The trial utilized a 400 mg dose of sibeprenlimab, administered via a subcutaneous injection every four weeks using a prefilled syringe designed for convenient self-administration at home.

Limitations and Cross-Treatment Comparisons

While the data is highly encouraging, healthcare providers and patients must consider several limitations:

• Pending 24-Month Data: The confirmatory study measuring long-term eGFR decline over a full 24 months is still ongoing, with final data expected later in 2026.

• Lifelong Maintenance Likely: Research indicates that APRIL levels return to baseline once sibeprenlimab is discontinued, suggesting that most patients will require long-term, uninterrupted treatment to maintain kidney protection.

Nonetheless, when compared to other existing and emerging IgAN therapies, VOYXACT’s 9-month data holds a highly competitive edge in efficacy.

9-Month Proteinuria Reduction Comparison

[VOYXACT (Sibeprenlimab)] ############################ 51.2%
[Atacicept (Vera)*]       ######################### 46.0% (at 36 weeks)
[Vanrafia]                ##################### 38.0%
[Tarpeyo]                 ################## 34.0%

Practical Implications for the Future

For nephrologists, VOYXACT introduces a highly targeted tool. Unlike traditional systemic corticosteroids that broadly suppress the immune system—leaving patients highly vulnerable to severe infections—this selective APRIL blockade isolates the disease pathway. Combined with the practical convenience of a once-a-month home injection rather than frequent, exhausting intravenous infusions at a hospital clinic, the therapy promises to substantially elevate the daily quality of life for those living with chronic kidney disease.

As the blinded VISIONARY study pushes forward to its 24-month conclusion, both the scientific community and IgAN patients await the final data to confirm whether this innovative molecule will fundamentally rewrite the prognosis of IgA nephropathy.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://www.reuters.com/business/healthcare-pharmaceuticals/otsuka-says-kidney-disease-drug-preserves-function-late-stage-study-2026-06-04/